Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and ifenprodil

sorafenib has been researched along with ifenprodil in 1 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(ifenprodil)		Trials
(ifenprodil)		Recent Studies (post-2010) (ifenprodil)
6,5207305,25168510207

Protein Interaction Comparison

ProteinTaxonomysorafenib (IC50)ifenprodil (IC50)
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)0.105
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)0.105
Histamine H1 receptorHomo sapiens (human)1
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)0.168
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)0.105
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)0.263
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)0.168
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)0.263
Glutamate receptor ionotropic, NMDA 1Homo sapiens (human)0.2039
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.1
Glutamate receptor ionotropic, NMDA 2BHomo sapiens (human)0.1519
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)0.263
5-hydroxytryptamine receptor 1AMus musculus (house mouse)0.238
5-hydroxytryptamine receptor 2ABos taurus (cattle)0.61
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)0.263
Sigma non-opioid intracellular receptor 1Homo sapiens (human)0.0039
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)0.263

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chan, BKC; Cheung, MSH; Choi, GCG; Chu, HY; Fong, JHC; Huang, Y; Ma, S; Mak, KH; Pardeshi, L; Tong, CSW; Tong, M; Wong, ASL; Wong, KH; Wong, TL; Xu, F1

Other Studies

1 other study(ies) available for sorafenib and ifenprodil

ArticleYear
A Combinatorial CRISPR-Cas9 Screen Identifies Ifenprodil as an Adjunct to Sorafenib for Liver Cancer Treatment.
    Cancer research, 2021, 12-15, Volume: 81, Issue:24

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; CRISPR-Cas Systems; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Piperidines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2021